You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameOxycodone
Accession NumberDB00497  (APRD00387)
TypeSmall Molecule
GroupsApproved, Illicit, Investigational
DescriptionOxycodone is a semisynthetic derivative of codeine that acts as a narcotic analgesic more potent and addicting than codeine. An extended-release (ER) form of oxycodone (Xtampza ER) was approved for the management of daily, around-the-clock pain management in April, 2016.
Structure
Thumb
Synonyms
(-)-14-Hydroxydihydrocodeinone
4,5-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one
4,5alpha-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one
4,5α-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one
Dihydro-14-hydroxycodeinone
Dihydrohydroxycodeinone
Dihydroxycodeinone
Oxicodona
Oxycodone
Oxycodonum
External Identifiers
  • PTI-821
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Act Oxycodone CRTablet, extended release5 mgOralActavis Pharma Company2012-11-26Not applicableCanada
Act Oxycodone CRTablet, extended release80 mgOralActavis Pharma Company2012-11-26Not applicableCanada
Act Oxycodone CRTablet, extended release10 mgOralActavis Pharma Company2012-11-26Not applicableCanada
Act Oxycodone CRTablet, extended release20 mgOralActavis Pharma Company2012-11-26Not applicableCanada
Act Oxycodone CRTablet, extended release40 mgOralActavis Pharma Company2012-11-26Not applicableCanada
OxaydoTablet7.5 mg/1OralEgalet Us Inc.2015-09-01Not applicableUs
OxaydoTablet5 mg/1OralLake Erie Medical DBA Quality Care Products LLC2015-09-01Not applicableUs
OxaydoTablet5 mg/1OralEgalet Us Inc.2015-09-01Not applicableUs
OxaydoTablet7.5 mg/1OralLake Erie Medical DBA Quality Care Products LLC2015-09-01Not applicableUs
OxectaTablet5 mg/1OralPfizer Laboratories Div Pfizer Inc2011-06-17Not applicableUs
OxectaTablet7.5 mg/1OralPfizer Laboratories Div Pfizer Inc2011-06-17Not applicableUs
Oxy.irTablet5 mgOralPurdue Pharma2000-03-31Not applicableCanada
Oxy.irTablet10 mgOralPurdue Pharma2000-03-31Not applicableCanada
Oxy.irTablet, multilayer, extended release20 mgOralPurdue Pharma2000-03-31Not applicableCanada
OxycodoneTablet5 mgOralPro Doc Limitee2009-06-10Not applicableCanada
OxycodoneTablet10 mgOralPro Doc Limitee2009-06-10Not applicableCanada
OxycodoneTablet20 mgOralPro Doc Limitee2009-06-10Not applicableCanada
Oxycodone HClTablet, film coated, extended release40 mg/1OralRanbaxy Pharmaceuticals Inc.2010-08-08Not applicableUs
Oxycodone HClTablet, film coated, extended release80 mg/1OralRanbaxy Pharmaceuticals Inc.2010-08-08Not applicableUs
Oxycodone HCl Controlled-releaseTablet10 mg/1OralRanbaxy Pharmaceuticals Inc2010-02-01Not applicableUs
Oxycodone HCl Controlled-releaseTablet20 mg/1OralRanbaxy Pharmaceuticals Inc2010-02-01Not applicableUs
Oxycodone HydrochlorideSolution5 mg/5mLOralVista Pharm Inc.2012-03-15Not applicableUs
Oxycodone HydrochlorideTablet, film coated, extended release20 mg/1OralSandoz Inc2014-10-08Not applicableUs
Oxycodone HydrochlorideTablet, film coated, extended release10 mg/1OralTeva Pharmaceuticals USA Inc2015-10-12Not applicableUs
Oxycodone HydrochlorideTablet, film coated, extended release30 mg/1OralImpax Generics2016-02-22Not applicableUs
Oxycodone HydrochlorideTablet, film coated, extended release10 mg/1OralLake Erie Medical DBA Quality Care Products LLC2016-02-22Not applicableUs
Oxycodone HydrochlorideSolution5 mg/5mLOralLehigh Valley Technologies, Inc.2013-09-09Not applicableUs
Oxycodone HydrochlorideTablet, film coated, extended release40 mg/1OralActavis Pharma, Inc.2014-09-03Not applicableUs
Oxycodone HydrochlorideTablet, film coated, extended release20 mg/1OralPar Pharmaceutical Companies, Inc2010-08-08Not applicableUs
Oxycodone HydrochlorideCapsule5 mg/1OralGlenmark Pharmaceuticals Inc., Usa2010-12-15Not applicableUs
Oxycodone HydrochlorideTablet, film coated, extended release10 mg/1OralImpax Generics2016-02-22Not applicableUs
Oxycodone HydrochlorideTablet, film coated, extended release40 mg/1OralSandoz Inc2014-10-08Not applicableUs
Oxycodone HydrochlorideCapsule5 mg/1Oralbryant ranch prepack2010-12-15Not applicableUs
Oxycodone HydrochlorideTablet, film coated, extended release20 mg/1OralTeva Pharmaceuticals USA Inc2015-10-12Not applicableUs
Oxycodone HydrochlorideTablet, film coated, extended release40 mg/1OralImpax Generics2016-02-22Not applicableUs
Oxycodone HydrochlorideTablet, film coated, extended release40 mg/1OralLake Erie Medical DBA Quality Care Products LLC2014-09-03Not applicableUs
Oxycodone HydrochlorideTablet, film coated, extended release40 mg/1OralPar Pharmaceutical Companies, Inc2010-08-08Not applicableUs
Oxycodone HydrochlorideCapsule5 mg/1OralAmerican Health Packaging2015-03-31Not applicableUs
Oxycodone HydrochlorideCapsule5 mg/1OralLehigh Valley Technologies, Inc.2010-10-20Not applicableUs
Oxycodone HydrochlorideTablet, film coated, extended release80 mg/1OralActavis Pharma, Inc.2014-09-03Not applicableUs
Oxycodone HydrochlorideTablet, film coated, extended release10 mg/1OralLake Erie Medical DBA Quality Care Products LLC2015-10-12Not applicableUs
Oxycodone HydrochlorideTablet, film coated, extended release80 mg/1OralSandoz Inc2014-10-08Not applicableUs
Oxycodone HydrochlorideSolution100 mg/5mLOralGlenmark Generics, Inc2010-12-20Not applicableUs
Oxycodone HydrochlorideTablet, film coated, extended release15 mg/1OralImpax Generics2016-02-22Not applicableUs
Oxycodone HydrochlorideTablet, film coated, extended release40 mg/1OralTeva Pharmaceuticals USA Inc2015-10-12Not applicableUs
Oxycodone HydrochlorideSolution, concentrate20 mg/mLOralSafecor Health, LLC2013-09-23Not applicableUs
Oxycodone HydrochlorideCapsule5 mg/1Oralbryant ranch prepack2010-12-15Not applicableUs
Oxycodone HydrochlorideTablet, film coated, extended release60 mg/1OralImpax Generics2016-02-22Not applicableUs
Oxycodone HydrochlorideTablet, film coated, extended release80 mg/1OralPar Pharmaceutical Companies, Inc2010-08-08Not applicableUs
Oxycodone HydrochlorideSolution5 mg/5mLOralVista Pharm Inc.2012-03-15Not applicableUs
Oxycodone HydrochlorideTablet, film coated, extended release10 mg/1OralSandoz Inc2014-10-08Not applicableUs
Oxycodone HydrochlorideTablet, film coated, extended release40 mg/1OralLake Erie Medical DBA Quality Care Products LLC2016-02-22Not applicableUs
Oxycodone HydrochlorideTablet, film coated, extended release20 mg/1OralImpax Generics2016-02-22Not applicableUs
Oxycodone HydrochlorideTablet, film coated, extended release80 mg/1OralTeva Pharmaceuticals USA Inc2015-10-12Not applicableUs
Oxycodone HydrochlorideTablet, film coated, extended release10 mg/1OralPar Pharmaceutical Companies, Inc2010-08-08Not applicableUs
Oxycodone HydrochlorideSolution100 mg/5mLOralLehigh Valley Technologies, Inc.2010-10-20Not applicableUs
Oxycodone HydrochlorideTablet, film coated, extended release80 mg/1OralImpax Generics2016-02-22Not applicableUs
Oxycodone Hydrochloride Controlled-releaseTablet, extended release40 mg/1OralEthex Corporation2009-09-25Not applicableUs
Oxycodone Hydrochloride Controlled-releaseTablet, extended release80 mg/1OralEthex Corporation2009-09-25Not applicableUs
Oxycodone Hydrochloride Controlled-releaseTablet, extended release10 mg/1OralEthex Corporation2009-09-25Not applicableUs
Oxycodone Hydrochloride Controlled-releaseTablet, extended release20 mg/1OralEthex Corporation2009-09-25Not applicableUs
OxycontinTablet, film coated, extended release40 mg/1OralLake Erie Medical DBA Quality Care Products LLC1995-12-01Not applicableUs
OxycontinTablet, film coated, extended release10 mg/1OralLake Erie Medical DBA Quality Care Products LLC2010-08-08Not applicableUs
OxycontinTablet, film coated, extended release20 mg/1OralPd Rx Pharmaceuticals, Inc.1995-12-01Not applicableUs
OxycontinTablet, film coated, extended release20 mg/1OralPurdue Pharma LP2010-08-08Not applicableUs
OxycontinTablet, film coated, extended release40 mg/1Oralbryant ranch prepack2010-08-08Not applicableUs
OxycontinTablet, film coated, extended release60 mg/1OralRebel Distributors Corp2010-08-08Not applicableUs
OxycontinTablet, film coated, extended release20 mg/1OralRebel Distributors Corp2010-08-08Not applicableUs
OxycontinTablet, film coated, extended release80 mg/1OralSTAT Rx USA LLC1997-01-01Not applicableUs
OxycontinTablet, film coated, extended release10 mg/1OralLake Erie Medical DBA Quality Care Products LLC2011-06-09Not applicableUs
OxycontinTablet, extended release60 mgOralPurdue Pharma2009-05-012012-09-26Canada
OxycontinTablet, film coated, extended release80 mg/1OralPurdue Pharma LP2010-08-08Not applicableUs
OxycontinTablet80 mg/1OralLake Erie Medical DBA Quality Care Products LLC2010-08-28Not applicableUs
OxycontinTablet, film coated, extended release20 mg/1OralLake Erie Medical DBA Quality Care Products LLC2010-08-08Not applicableUs
OxycontinTablet, film coated, extended release10 mg/1OralPd Rx Pharmaceuticals, Inc.2010-08-08Not applicableUs
OxycontinTablet, film coated, extended release30 mg/1OralPurdue Pharma LP2010-08-08Not applicableUs
OxycontinTablet20 mg/1OralSTAT Rx USA LLC2010-08-08Not applicableUs
OxycontinTablet, film coated, extended release30 mg/1OralSTAT Rx USA LLC2010-08-08Not applicableUs
OxycontinTablet, film coated, extended release20 mg/1OralLake Erie Medical DBA Quality Care Products LLC2011-06-09Not applicableUs
OxycontinTablet, film coated, extended release60 mg/1OralLake Erie Medical DBA Quality Care Products LLC2010-08-08Not applicableUs
OxycontinTablet, film coated, extended release40 mg/1OralPurdue Pharma LP2010-08-08Not applicableUs
OxycontinTablet, film coated, extended release10 mg/1Oralbryant ranch prepack2010-08-08Not applicableUs
OxycontinTablet, extended release15 mgOralPurdue Pharma2009-05-012012-09-26Canada
OxycontinTablet, film coated, extended release10 mg/1OralPurdue Pharma LP2010-08-08Not applicableUs
OxycontinTablet, film coated, extended release80 mg/1OralPd Rx Pharmaceuticals, Inc.1997-01-01Not applicableUs
OxycontinTablet, film coated, extended release20 mg/1OralSt Marys Medical Park Pharmacy2010-12-30Not applicableUs
OxycontinTablet, film coated, extended release60 mg/1OralLake Erie Medical DBA Quality Care Products LLC2011-06-09Not applicableUs
OxycontinTablet, film coated, extended release20 mg/1OralSTAT Rx USA LLC2010-08-08Not applicableUs
OxycontinTablet, film coated, extended release80 mg/1OralLake Erie Medical DBA Quality Care Products LLC2010-08-08Not applicableUs
OxycontinTablet, extended release30 mgOralPurdue Pharma2009-05-012012-09-26Canada
OxycontinTablet, film coated, extended release60 mg/1OralPurdue Pharma LP2010-08-08Not applicableUs
OxycontinTablet, film coated, extended release15 mg/1OralPurdue Pharma LP2010-08-08Not applicableUs
OxycontinTablet, film coated, extended release20 mg/1Oralbryant ranch prepack2010-08-08Not applicableUs
OxycontinTablet, film coated, extended release40 mg/1OralPd Rx Pharmaceuticals, Inc.1995-12-01Not applicableUs
OxycontinTablet, film coated, extended release80 mg/1OralRebel Distributors Corp2010-08-08Not applicableUs
Oxycontin 10mgTablet, extended release10 mgOralPurdue Pharma1996-12-312012-09-26Canada
Oxycontin 20mgTablet, extended release20 mgOralPurdue Pharma1996-12-312012-09-26Canada
Oxycontin 40mgTablet, extended release40 mgOralPurdue Pharma1996-12-312012-09-26Canada
Oxycontin 5mgTablet, extended release5 mgOralPurdue Pharma2005-04-012012-09-26Canada
Oxycontin 80mgTablet, extended release80 mgOralPurdue Pharma1996-12-312012-09-26Canada
OxyneoTablet, extended release10 mgOralPurdue Pharma2011-09-13Not applicableCanada
OxyneoTablet, extended release60 mgOralPurdue Pharma2011-09-13Not applicableCanada
OxyneoTablet, extended release15 mgOralPurdue Pharma2011-09-13Not applicableCanada
OxyneoTablet, extended release80 mgOralPurdue Pharma2011-09-13Not applicableCanada
OxyneoTablet, extended release30 mgOralPurdue Pharma2011-09-13Not applicableCanada
OxyneoTablet, extended release20 mgOralPurdue Pharma2011-09-13Not applicableCanada
OxyneoTablet, extended release40 mgOralPurdue Pharma2011-09-13Not applicableCanada
PMS-oxycodoneTablet20 mgOralPharmascience Inc2008-12-03Not applicableCanada
PMS-oxycodoneTablet5 mgOralPharmascience Inc2008-12-03Not applicableCanada
PMS-oxycodoneTablet10 mgOralPharmascience Inc2008-12-03Not applicableCanada
PMS-oxycodone CRTablet, extended release40 mgOralPharmascience Inc2012-11-27Not applicableCanada
PMS-oxycodone CRTablet, extended release15 mgOralPharmascience IncNot applicableNot applicableCanada
PMS-oxycodone CRTablet, extended release80 mgOralPharmascience Inc2012-11-27Not applicableCanada
PMS-oxycodone CRTablet, extended release30 mgOralPharmascience IncNot applicableNot applicableCanada
PMS-oxycodone CRTablet, extended release10 mgOralPharmascience Inc2012-11-27Not applicableCanada
PMS-oxycodone CRTablet, extended release60 mgOralPharmascience IncNot applicableNot applicableCanada
PMS-oxycodone CRTablet, extended release20 mgOralPharmascience Inc2012-11-27Not applicableCanada
PMS-oxycodone CRTablet, extended release5 mgOralPharmascience IncNot applicableNot applicableCanada
Ran-oxycodone CRTablet, extended release20 mgOralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Ran-oxycodone CRTablet, extended release40 mgOralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Ran-oxycodone CRTablet, extended release60 mgOralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Ran-oxycodone CRTablet, extended release80 mgOralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Ran-oxycodone CRTablet, extended release15 mgOralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Riva-oxycodone CRTablet, extended release10 mgOralLaboratoire Riva IncNot applicableNot applicableCanada
Riva-oxycodone CRTablet, extended release20 mgOralLaboratoire Riva IncNot applicableNot applicableCanada
Riva-oxycodone CRTablet, extended release40 mgOralLaboratoire Riva IncNot applicableNot applicableCanada
Riva-oxycodone CRTablet, extended release80 mgOralLaboratoire Riva IncNot applicableNot applicableCanada
RoxicodoneTablet5 mg/1OralMallinckrodt, Inc2009-08-26Not applicableUs
RoxicodoneTablet15 mg/1OralMallinckrodt, Inc2000-08-31Not applicableUs
RoxicodoneTablet30 mg/1OralSTAT Rx USA LLC2000-08-31Not applicableUs
RoxicodoneTablet30 mg/1OralMallinckrodt, Inc2000-08-31Not applicableUs
Sandoz Oxycodone CRTablet, extended release40 mgOralSandoz Canada IncorporatedNot applicableNot applicableCanada
Sandoz Oxycodone CRTablet, extended release80 mgOralSandoz Canada IncorporatedNot applicableNot applicableCanada
Sandoz Oxycodone CRTablet, extended release10 mgOralSandoz Canada IncorporatedNot applicableNot applicableCanada
Sandoz Oxycodone CRTablet, extended release5 mgOralSandoz Canada IncorporatedNot applicableNot applicableCanada
Sandoz Oxycodone CRTablet, extended release20 mgOralSandoz Canada IncorporatedNot applicableNot applicableCanada
SupeudolTablet20 mgOralSandoz Canada Incorporated2005-04-26Not applicableCanada
Supeudol 10Tablet10 mgOralSandoz Canada Incorporated1980-12-31Not applicableCanada
Supeudol 10Suppository10 mgRectalSandoz Canada Incorporated1973-12-31Not applicableCanada
Supeudol 20Suppository20 mgRectalSandoz Canada Incorporated1973-12-31Not applicableCanada
Supeudol 5Tablet5 mgOralSandoz Canada Incorporated1990-12-31Not applicableCanada
Teva-oxycodone CRTablet, extended release80 mgOralTeva Canada LimitedNot applicableNot applicableCanada
Teva-oxycodone CRTablet, extended release10 mgOralTeva Canada LimitedNot applicableNot applicableCanada
Teva-oxycodone CRTablet, extended release20 mgOralTeva Canada LimitedNot applicableNot applicableCanada
Teva-oxycodone CRTablet, extended release40 mgOralTeva Canada LimitedNot applicableNot applicableCanada
Xtampza ERCapsule, extended release9 mg/1OralCollegium Pharmaceutical, Inc.2016-05-10Not applicableUs
Xtampza ERCapsule, extended release36 mg/1OralCollegium Pharmaceutical, Inc.2016-05-10Not applicableUs
Xtampza ERCapsule, extended release13.5 mg/1OralCollegium Pharmaceutical, Inc.2016-05-10Not applicableUs
Xtampza ERCapsule, extended release18 mg/1OralCollegium Pharmaceutical, Inc.2016-05-10Not applicableUs
Xtampza ERCapsule, extended release27 mg/1OralCollegium Pharmaceutical, Inc.2016-05-10Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-oxycodone CRTablet, extended release5.0 mgOralApotex Inc2012-11-26Not applicableCanada
Apo-oxycodone CRTablet, extended release15 mgOralApotex Inc2012-11-27Not applicableCanada
Apo-oxycodone CRTablet, extended release10.0 mgOralApotex Inc2012-11-26Not applicableCanada
Apo-oxycodone CRTablet, extended release30 mgOralApotex Inc2012-11-27Not applicableCanada
Apo-oxycodone CRTablet, extended release20.0 mgOralApotex Inc2012-11-26Not applicableCanada
Apo-oxycodone CRTablet, extended release60 mgOralApotex Inc2012-11-27Not applicableCanada
Apo-oxycodone CRTablet, extended release80.0 mgOralApotex Inc2012-11-26Not applicableCanada
Apo-oxycodone CRTablet, extended release40 mgOralApotex Inc2012-11-26Not applicableCanada
Oxycodone HClTablet15 mg/1OralDIRECT RX2016-02-08Not applicableUs
Oxycodone HClTablet30 mg/1OralDIRECT RX2016-02-22Not applicableUs
Oxycodone HydchlorideTablet5 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-12-20Not applicableUs
Oxycodone HydchlorideTablet10 mg/1OralLake Erie Medical DBA Quality Care Products LLC2011-12-20Not applicableUs
Oxycodone HydrochlorideTablet15 mg/1OralCore Pharma, Llc2009-10-27Not applicableUs
Oxycodone HydrochlorideSolution100 mg/5mLOralMayne Pharma Inc.2014-06-12Not applicableUs
Oxycodone HydrochlorideCapsule5 mg/1OralMayne Pharma Inc.2012-07-31Not applicableUs
Oxycodone HydrochlorideTablet5 mg/1OralMayne Pharma Inc.2011-02-28Not applicableUs
Oxycodone HydrochlorideCapsule5 mg/1OralKvk Tech, Inc.2015-08-20Not applicableUs
Oxycodone HydrochlorideSolution20 mg/mLOralNovel Laboratories, Inc.2015-04-29Not applicableUs
Oxycodone HydrochlorideTablet30 mg/1OralMylan Pharmaceuticals Inc.2011-02-28Not applicableUs
Oxycodone HydrochlorideSolution20 mg/mLOralGAVIS Pharmaceuticals, LLC2015-07-01Not applicableUs
Oxycodone HydrochlorideTablet5 mg/1OralPhysicians Total Care, Inc.2009-12-18Not applicableUs
Oxycodone HydrochlorideTablet10 mg/1OralGolden State Medical Supply, Inc.2015-09-10Not applicableUs
Oxycodone HydrochlorideTablet15 mg/1Oralbryant ranch prepack2009-06-01Not applicableUs
Oxycodone HydrochlorideTablet15 mg/1OralDispensing Solutions, Inc.2009-07-30Not applicableUs
Oxycodone HydrochlorideSolution5 mg/5mLOralWest Ward Pharmaceuticals Corp.2014-09-04Not applicableUs
Oxycodone HydrochlorideTablet15 mg/1OralMajor Pharmaceuticals2015-06-01Not applicableUs
Oxycodone HydrochlorideTablet20 mg/1OralMayne Pharma Inc.2011-02-28Not applicableUs
Oxycodone HydrochlorideTablet5 mg/1OralRebel Distributors Corp2009-03-02Not applicableUs
Oxycodone HydrochlorideSolution100 mg/5mLOralRoxane Laboratories, Inc.2013-07-16Not applicableUs
Oxycodone HydrochlorideTablet20 mg/1OralRhodes Pharmaceuticals L.P.2014-09-08Not applicableUs
Oxycodone HydrochlorideTablet10 mg/1OralUnit Dose Services2012-12-26Not applicableUs
Oxycodone HydrochlorideTablet30 mg/1OralLake Erie Medical DBA Quality Care Products LLC2013-10-18Not applicableUs
Oxycodone HydrochlorideSolution100 mg/5mLOralAtlantic Biologicals Corps2015-01-01Not applicableUs
Oxycodone HydrochlorideTablet15 mg/1OralAurolife Pharma LLC2012-07-12Not applicableUs
Oxycodone HydrochlorideTablet30 mg/1OralSTAT Rx USA LLC2007-01-31Not applicableUs
Oxycodone HydrochlorideTablet30 mg/1OralQualitest Pharmaceuticals2007-01-31Not applicableUs
Oxycodone HydrochlorideTablet15 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-02-14Not applicableUs
Oxycodone HydrochlorideTablet15 mg/1OralPd Rx Pharmaceuticals, Inc.2010-01-01Not applicableUs
Oxycodone HydrochlorideSolution5 mg/5mLOralMorton Grove Pharmaceuticals, Inc.2015-06-17Not applicableUs
Oxycodone HydrochlorideTablet15 mg/1OralAmneal Pharmaceuticals of New York, LLC2012-10-30Not applicableUs
Oxycodone HydrochlorideTablet15 mg/1OralZydus Pharmaceuticals (USA) Inc.2012-12-26Not applicableUs
Oxycodone HydrochlorideTablet5 mg/1OralEpic Pharma, LLC2015-09-22Not applicableUs
Oxycodone HydrochlorideTablet30 mg/1OralMallinckrodt, Inc.2009-07-30Not applicableUs
Oxycodone HydrochlorideTablet15 mg/1OralKvk Tech,Inc2013-10-18Not applicableUs
Oxycodone HydrochlorideTablet15 mg/1OralLake Erie Medical DBA Quality Care Products LLC2009-05-12Not applicableUs
Oxycodone HydrochlorideTablet30 mg/1OralActavis Pharma, Inc.2010-12-24Not applicableUs
Oxycodone HydrochlorideTablet5 mg/1OralPd Rx Pharmaceuticals, Inc.2009-03-02Not applicableUs
Oxycodone HydrochlorideTablet5 mg/1OralH.J. Harkins Company, Inc.2009-03-02Not applicableUs
Oxycodone HydrochlorideTablet10 mg/1OralSun Pharmaceutical Industries, Inc.2012-11-19Not applicableUs
Oxycodone HydrochlorideTablet10 mg/1Oralbryant ranch prepack2012-12-26Not applicableUs
Oxycodone HydrochlorideTablet30 mg/1OralAmerican Health Packaging2010-01-15Not applicableUs
Oxycodone HydrochlorideTablet15 mg/1OralGolden State Medical Supply, Inc.2015-09-10Not applicableUs
Oxycodone HydrochlorideTablet30 mg/1OralCore Pharma, Llc2009-10-27Not applicableUs
Oxycodone HydrochlorideTablet5 mg/1OralMayne Pharma Inc.2011-02-28Not applicableUs
Oxycodone HydrochlorideTablet15 mg/1OralMayne Pharma Inc.2011-02-28Not applicableUs
Oxycodone HydrochlorideTablet10 mg/1OralKvk Tech,Inc2013-10-18Not applicableUs
Oxycodone HydrochlorideCapsule5 mg/1OralNovel Laboratories, Inc.2015-08-24Not applicableUs
Oxycodone HydrochlorideSolution100 mg/5mLOralLannett Company, Inc.2014-09-10Not applicableUs
Oxycodone HydrochlorideTablet5 mg/1OralAlvogen, Inc.2011-11-03Not applicableUs
Oxycodone HydrochlorideTablet30 mg/1OralPhysicians Total Care, Inc.2008-10-01Not applicableUs
Oxycodone HydrochlorideTablet15 mg/1OralUnit Dose Services2012-12-26Not applicableUs
Oxycodone HydrochlorideTablet15 mg/1OralSun Pharmaceutical Industries, Inc.2009-05-12Not applicableUs
Oxycodone HydrochlorideTablet30 mg/1Oralbryant ranch prepack2010-03-04Not applicableUs
Oxycodone HydrochlorideSolution100 mg/5mLOralVista Pharm, Inc.2012-08-15Not applicableUs
Oxycodone HydrochlorideSolution100 mg/5mLOralWest Ward Pharmaceuticals Corp.2014-09-04Not applicableUs
Oxycodone HydrochlorideTablet30 mg/1OralBlenheim Pharmacal, Inc.2010-06-16Not applicableUs
Oxycodone HydrochlorideTablet5 mg/1OralRed Pharm Drug, Inc.2013-10-18Not applicableUs
Oxycodone HydrochlorideTablet10 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-02-14Not applicableUs
Oxycodone HydrochlorideSolution5 mg/5mLOralRoxane Laboratories, Inc.2013-07-15Not applicableUs
Oxycodone HydrochlorideTablet30 mg/1OralRhodes Pharmaceuticals L.P.2014-09-08Not applicableUs
Oxycodone HydrochlorideTablet20 mg/1OralZydus Pharmaceuticals (USA) Inc.2012-12-26Not applicableUs
Oxycodone HydrochlorideTablet10 mg/1OralEpic Pharma, LLC2015-09-22Not applicableUs
Oxycodone HydrochlorideCapsule5 mg/1OralANI Pharmaceuticals, Inc.2016-06-10Not applicableUs
Oxycodone HydrochlorideTablet30 mg/1OralAurolife Pharma LLC2012-07-12Not applicableUs
Oxycodone HydrochlorideTablet5 mg/1OralRhodes Pharmaceuticals L.P.2014-09-08Not applicableUs
Oxycodone HydrochlorideTablet10 mg/1OralQualitest Pharmaceuticals2015-04-13Not applicableUs
Oxycodone HydrochlorideTablet30 mg/1OralLake Erie Medical DBA Quality Care Products LLC2010-08-19Not applicableUs
Oxycodone HydrochlorideTablet15 mg/1OralPd Rx Pharmaceuticals, Inc.2010-01-01Not applicableUs
Oxycodone HydrochlorideTablet5 mg/1OralSt Marys Medical Park Pharmacy2013-01-10Not applicableUs
Oxycodone HydrochlorideTablet20 mg/1OralAmneal Pharmaceuticals of New York, LLC2012-10-30Not applicableUs
Oxycodone HydrochlorideTablet5 mg/1OralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation2012-12-26Not applicableUs
Oxycodone HydrochlorideTablet5 mg/1OralAmerican Health Packaging2009-12-09Not applicableUs
Oxycodone HydrochlorideCapsule5 mg/1OralLannett Company, Inc.2014-08-01Not applicableUs
Oxycodone HydrochlorideTablet30 mg/1OralKvk Tech,Inc2013-10-18Not applicableUs
Oxycodone HydrochlorideTablet30 mg/1OralLake Erie Medical DBA Quality Care Products LLC2009-05-12Not applicableUs
Oxycodone HydrochlorideTablet5 mg/1OralMylan Pharmaceuticals Inc.2011-02-28Not applicableUs
Oxycodone HydrochlorideTablet20 mg/1OralPd Rx Pharmaceuticals, Inc.2013-10-18Not applicableUs
Oxycodone HydrochlorideTablet10 mg/1OralPhysicians Total Care, Inc.2008-06-06Not applicableUs
Oxycodone HydrochlorideTablet20 mg/1OralSun Pharmaceutical Industries, Inc.2012-11-19Not applicableUs
Oxycodone HydrochlorideTablet5 mg/1OralQualitest Pharmaceuticals2009-03-02Not applicableUs
Oxycodone HydrochlorideTablet15 mg/1OralAlvogen, Inc.2011-11-03Not applicableUs
Oxycodone HydrochlorideTablet20 mg/1OralPhysicians Total Care, Inc.2008-06-06Not applicableUs
Oxycodone HydrochlorideTablet20 mg/1OralGolden State Medical Supply, Inc.2015-09-10Not applicableUs
Oxycodone HydrochlorideTablet5 mg/1OralAmneal Pharmaceuticals of New York, LLC2012-10-30Not applicableUs
Oxycodone HydrochlorideTablet5 mg/1OralZydus Pharmaceuticals (USA) Inc.2012-12-26Not applicableUs
Oxycodone HydrochlorideTablet30 mg/1OralMayne Pharma Inc.2011-02-28Not applicableUs
Oxycodone HydrochlorideTablet20 mg/1OralKvk Tech,Inc2013-10-18Not applicableUs
Oxycodone HydrochlorideTablet5 mg/1OralSTAT Rx USA LLC2007-03-19Not applicableUs
Oxycodone HydrochlorideTablet20 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-12-20Not applicableUs
Oxycodone HydrochlorideTablet5 mg/1OralActavis Pharma, Inc.2015-08-03Not applicableUs
Oxycodone HydrochlorideTablet15 mg/1OralPd Rx Pharmaceuticals, Inc.2010-01-01Not applicableUs
Oxycodone HydrochlorideTablet15 mg/1OralH.J. Harkins Company, Inc.2007-01-31Not applicableUs
Oxycodone HydrochlorideTablet5 mg/1OralSun Pharmaceutical Industries, Inc.2009-05-12Not applicableUs
Oxycodone HydrochlorideCapsule5 mg/1Oralbryant ranch prepack2010-03-08Not applicableUs
Oxycodone HydrochlorideTablet10 mg/1OralAmerican Health Packaging2014-09-25Not applicableUs
Oxycodone HydrochlorideTablet5 mg/1OralMallinckrodt, Inc.2009-07-30Not applicableUs
Oxycodone HydrochlorideTablet30 mg/1OralBlenheim Pharmacal, Inc.2010-04-06Not applicableUs
Oxycodone HydrochlorideTablet30 mg/1OralAmneal Pharmaceuticals of New York, LLC2012-10-30Not applicableUs
Oxycodone HydrochlorideTablet30 mg/1OralZydus Pharmaceuticals (USA) Inc.2012-12-26Not applicableUs
Oxycodone HydrochlorideTablet15 mg/1OralEpic Pharma, LLC2015-09-22Not applicableUs
Oxycodone HydrochlorideSolution100 mg/5mLOralPrecision Dose, Inc.2016-07-01Not applicableUs
Oxycodone HydrochlorideTablet15 mg/1OralSTAT Rx USA LLC2007-01-31Not applicableUs
Oxycodone HydrochlorideTablet10 mg/1OralRhodes Pharmaceuticals L.P.2014-09-08Not applicableUs
Oxycodone HydrochlorideTablet20 mg/1OralQualitest Pharmaceuticals2015-04-13Not applicableUs
Oxycodone HydrochlorideTablet10 mg/1OralLake Erie Medical DBA Quality Care Products LLC2012-11-19Not applicableUs
Oxycodone HydrochlorideTablet15 mg/1OralSt Marys Medical Park Pharmacy2011-01-11Not applicableUs
Oxycodone HydrochlorideTablet5 mg/1OralCore Pharma, Llc2009-10-27Not applicableUs
Oxycodone HydrochlorideTablet20 mg/1OralAmerican Health Packaging2014-09-25Not applicableUs
Oxycodone HydrochlorideTablet5 mg/1OralPd Rx Pharmaceuticals, Inc.2013-10-18Not applicableUs
Oxycodone HydrochlorideTablet5 mg/1OralKvk Tech,Inc2013-10-18Not applicableUs
Oxycodone HydrochlorideTablet15 mg/1OralMylan Pharmaceuticals Inc.2011-02-28Not applicableUs
Oxycodone HydrochlorideTablet10 mg/1OralPd Rx Pharmaceuticals, Inc.2013-10-18Not applicableUs
Oxycodone HydrochlorideTablet15 mg/1OralPhysicians Total Care, Inc.2008-01-16Not applicableUs
Oxycodone HydrochlorideTablet5 mg/1OralGolden State Medical Supply, Inc.2015-09-10Not applicableUs
Oxycodone HydrochlorideTablet15 mg/1OralSTAT Rx USA LLC2007-01-31Not applicableUs
Oxycodone HydrochlorideTablet15 mg/1OralQualitest Pharmaceuticals2007-01-31Not applicableUs
Oxycodone HydrochlorideTablet30 mg/1OralAlvogen, Inc.2011-11-03Not applicableUs
Oxycodone HydrochlorideTablet30 mg/1OralPd Rx Pharmaceuticals, Inc.2007-01-31Not applicableUs
Oxycodone HydrochlorideTablet30 mg/1OralGolden State Medical Supply, Inc.2015-09-10Not applicableUs
Oxycodone HydrochlorideTablet10 mg/1OralAmneal Pharmaceuticals of New York, LLC2012-10-30Not applicableUs
Oxycodone HydrochlorideTablet10 mg/1OralZydus Pharmaceuticals (USA) Inc.2012-12-26Not applicableUs
Oxycodone HydrochlorideTablet5 mg/1OralAvera Mc Kennan Hospital2015-05-15Not applicableUs
Oxycodone HydrochlorideSolution5 mg/5mLOralPharmaceutical Associates, Inc.2016-05-16Not applicableUs
Oxycodone HydrochlorideTablet5 mg/1OralAurolife Pharma LLC2012-07-12Not applicableUs
Oxycodone HydrochlorideTablet5 mg/1OralLake Erie Medical DBA Quality Care Products LLC2009-05-12Not applicableUs
Oxycodone HydrochlorideTablet15 mg/1OralActavis Pharma, Inc.2010-12-24Not applicableUs
Oxycodone HydrochlorideTablet30 mg/1OralPd Rx Pharmaceuticals, Inc.2007-01-31Not applicableUs
Oxycodone HydrochlorideTablet30 mg/1OralH.J. Harkins Company, Inc.2011-02-28Not applicableUs
Oxycodone HydrochlorideTablet30 mg/1OralSun Pharmaceutical Industries, Inc.2009-05-12Not applicableUs
Oxycodone HydrochlorideTablet5 mg/1Oralbryant ranch prepack2009-03-02Not applicableUs
Oxycodone HydrochlorideTablet15 mg/1OralAmerican Health Packaging2010-01-15Not applicableUs
Oxycodone HydrochlorideTablet15 mg/1OralMallinckrodt, Inc.2009-07-30Not applicableUs
Oxycodone HydrochlorideTablet15 mg/1OralBlenheim Pharmacal, Inc.2010-04-06Not applicableUs
Oxycodone HydrochlorideTablet30 mg/1OralDispensing Solutions, Inc.2009-07-30Not applicableUs
Oxycodone HydrochlorideTablet30 mg/1OralEpic Pharma, LLC2015-09-22Not applicableUs
Oxycodone HydrochlorideTablet10 mg/1OralMayne Pharma Inc.2011-02-28Not applicableUs
Oxycodone HydrochlorideTablet5 mg/1OralSTAT RX LLC USA2009-07-30Not applicableUs
Oxycodone HydrochlorideTablet15 mg/1OralRhodes Pharmaceuticals L.P.2014-09-08Not applicableUs
Oxycodone HydrochlorideTablet5 mg/1OralMajor Pharmaceuticals2015-02-05Not applicableUs
Oxycodone HydrochlorideTablet5 mg/1OralUnit Dose Services2012-12-26Not applicableUs
Oxycodone HydrochlorideTablet15 mg/1OralLake Erie Medical DBA Quality Care Products LLC2013-10-18Not applicableUs
Oxycodone HydrochlorideSolution5 mg/5mLOralANI Pharmaceuticals, Inc.2015-10-13Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
OxanestNot Available
OxyIRNot Available
Brand mixtures
NameLabellerIngredients
Apo-oxycodone/acetApotex Inc
EndocetSTAT Rx USA LLC
EndodanSTAT Rx USA LLC
Ntp-oxycodone AcetaminophenNt Pharma Canada Ltd
Nu-oxycodone/acetNu Pharm Inc
Oxycodone and AcetaminophenMylan Pharmaceuticals Inc.
Oxycodone and AspirinPhysicians Total Care, Inc.
Oxycodone ApapDIRECT RX
Oxycodone Hydrochloride and AcetaminophenRoxane Laboratories, Inc
Oxycodone Hydrochloride and AspirinMylan Pharmaceuticals Inc.
Oxycodone Hydrochloride and IbuprofenLake Erie Medical DBA Quality Care Products LLC
Oxycodone-acetPro Doc Limitee
Oxycodone/acetSanis Health Inc
Oxycodone/acetaminophenNt Pharma Canada Ltd
PercocetSTAT Rx USA LLC
Percocet-demiBristol Myers Squibb Canada
PercodanEndo Pharmaceuticals Inc
Percodan-demiBristol Myers Squibb Canada
PMS-oxycodone - AcetaminophenPharmascience Inc
PrimlevAkrimax Pharmaceuticals, LLC
Ratio-oxycocetTeva Canada Limited
Ratio-oxycodanTeva Canada Limited
RivacocetLaboratoire Riva Inc
RivacodanLaboratoire Riva Inc
RoxicetRoxane Laboratories, Inc.
Roxicet TabRoxane Labs, Division Of Boehringer Ingelheim
Sandoz Oxycodone/acetaminophenSandoz Canada Incorporated
TarginPurdue Pharma
Troxyca ERPfizer Laboratories Div Pfizer Inc
Xartemis XRMallinckrodt, Inc
XoloxRebel Distributors Corp
Salts
Name/CASStructureProperties
Oxycodone hydrochloride
124-90-3
Thumb
  • InChI Key: MUZQPDBAOYKNLO-RKXJKUSZSA-N
  • Monoisotopic Mass: 351.123735904
  • Average Mass: 351.825
DBSALT000277
Oxycodone terephthalate
ThumbNot applicableDBSALT001326
Categories
UNIICD35PMG570
CAS number76-42-6
WeightAverage: 315.3636
Monoisotopic: 315.147058165
Chemical FormulaC18H21NO4
InChI KeyBRUQQQPBMZOVGD-XFKAJCMBSA-N
InChI
InChI=1S/C18H21NO4/c1-19-8-7-17-14-10-3-4-12(22-2)15(14)23-16(17)11(20)5-6-18(17,21)13(19)9-10/h3-4,13,16,21H,5-9H2,1-2H3/t13-,16+,17+,18-/m1/s1
IUPAC Name
(1S,5R,13R,17S)-17-hydroxy-10-methoxy-4-methyl-12-oxa-4-azapentacyclo[9.6.1.0¹,¹³.0⁵,¹⁷.0⁷,¹⁸]octadeca-7(18),8,10-trien-14-one
SMILES
[H][C@@]12OC3=C(OC)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1(O)CCC2=O
Pharmacology
IndicationFor the treatment of diarrhoea, pulmonary oedema and for the relief of moderate to moderately severe pain.
Structured Indications
PharmacodynamicsOxycodone, a semisynthetic opiate agonist derived from the opioid alkaloid, thebaine, is similar to other phenanthrene derivatives such as hydrocodone and morphine. Oxycodone is available in combination with aspirin or acetaminophen to control pain and restless leg and Tourette syndromes.
Mechanism of actionOxycodone acts as a weak agonist at mu, kappa, and delta opioid receptors within the central nervous system (CNS). Oxycodone primarily affects mu-type opioid receptors, which are coupled with G-protein receptors and function as modulators, both positive and negative, of synaptic transmission via G-proteins that activate effector proteins. Binding of the opiate stimulates the exchange of GTP for GDP on the G-protein complex. As the effector system is adenylate cyclase and cAMP located at the inner surface of the plasma membrane, opioids decrease intracellular cAMP by inhibiting adenylate cyclase. Subsequently, the release of nociceptive neurotransmitters such as substance P, GABA, dopamine, acetylcholine, and noradrenaline is inhibited. Opioids such as oxycodone also inhibit the release of vasopressin, somatostatin, insulin, and glucagon. Opioids close N-type voltage-operated calcium channels (kappa-receptor agonist) and open calcium-dependent inwardly rectifying potassium channels (mu and delta receptor agonist). This results in hyperpolarization and reduced neuronal excitability.
TargetKindPharmacological actionActionsOrganismUniProt ID
Mu-type opioid receptorProteinyes
agonist
HumanP35372 details
Kappa-type opioid receptorProteinyes
agonist
HumanP41145 details
Delta-type opioid receptorProteinyes
agonist
HumanP41143 details
Kappa-type opioid receptor 2bProteinunknown
agonist
Humannot applicabledetails
alpha1-acid glycoproteinProtein groupunknown
binder
Humannot applicabledetails
Related Articles
AbsorptionWell absorbed with an oral bioavailability of 60% to 87%
Volume of distribution
  • 2.6 L/kg
Protein binding45%
Metabolism

Hepatic

SubstrateEnzymesProduct
Oxycodone
oxymorphoneDetails
Oxycodone
noroxycodoneDetails
Route of eliminationOxycodone and its metabolites are excreted primarily via the kidney.
Half life4.5 hours
Clearance
  • 0.8 L/min [adults]
ToxicitySymptoms of overdose include respiratory depression, somnolence progressing to stupor or coma, skeletal muscle flaccidity, cold and clammy skin, constricted pupils, bradycardia, hypotension, and death.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Oxycodone Action PathwayDrug actionSMP00409
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when Oxycodone is combined with 1,1,1,2 Tetrafluoroethane.Investigational
2,5-Dimethoxy-4-ethylamphetamine2,5-Dimethoxy-4-ethylamphetamine may increase the analgesic activities of Oxycodone.Experimental, Illicit
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may increase the analgesic activities of Oxycodone.Experimental, Illicit
3,4-Methylenedioxymethamphetamine3,4-Methylenedioxymethamphetamine may increase the analgesic activities of Oxycodone.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamine4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Oxycodone.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when Oxycodone is combined with 7-Nitroindazole.Experimental
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINEThe risk or severity of adverse effects can be increased when 7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE is combined with Oxycodone.Experimental
AbirateroneThe serum concentration of Oxycodone can be increased when it is combined with Abiraterone.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Aceprometazine.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Acetazolamide.Approved, Vet Approved
AclidiniumThe risk or severity of adverse effects can be increased when Aclidinium is combined with Oxycodone.Approved
adipiplonThe risk or severity of adverse effects can be increased when Oxycodone is combined with adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Agomelatine.Approved, Investigational
AlfaxaloneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Oxycodone is combined with Alfentanil.Approved, Illicit
AlimemazineAlimemazine may increase the hypotensive activities of Oxycodone.Approved, Vet Approved
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Oxycodone is combined with Alphacetylmethadol.Experimental, Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Oxycodone.Approved, Illicit, Investigational
AlvimopanThe risk or severity of adverse effects can be increased when Oxycodone is combined with Alvimopan.Approved
AmilorideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Amiloride.Approved
AmiodaroneThe risk or severity of adverse effects can be increased when Amiodarone is combined with Oxycodone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Amitriptyline.Approved
Ammonium chlorideAmmonium chloride may increase the excretion rate of Oxycodone which could result in a lower serum level and potentially a reduction in efficacy.Approved, Vet Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Oxycodone is combined with Amobarbital.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Amperozide.Experimental
AmphetamineAmphetamine may increase the analgesic activities of Oxycodone.Approved, Illicit
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Oxycodone.Approved
AprepitantThe risk or severity of adverse effects can be increased when Aprepitant is combined with Oxycodone.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Oxycodone is combined with Aripiprazole.Approved, Investigational
ArtemetherThe metabolism of Oxycodone can be decreased when combined with Artemether.Approved
ArticaineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Asenapine.Approved
AtazanavirThe risk or severity of adverse effects can be increased when Atazanavir is combined with Oxycodone.Approved, Investigational
AtomoxetineThe risk or severity of adverse effects can be increased when Atomoxetine is combined with Oxycodone.Approved
Atracurium besylateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Oxycodone.Approved
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Oxycodone.Approved, Vet Approved
AzaperoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Azaperone.Vet Approved
AzelastineOxycodone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Azelastine.Approved
AzosemideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Azosemide.Investigational
BaclofenThe risk or severity of adverse effects can be increased when Oxycodone is combined with Baclofen.Approved
BarbitalThe risk or severity of adverse effects can be increased when Oxycodone is combined with Barbital.Illicit
BenactyzineThe risk or severity of adverse effects can be increased when Benactyzine is combined with Oxycodone.Withdrawn
BendroflumethiazideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Bendroflumethiazide.Approved
BenmoxinThe risk or severity of adverse effects can be increased when Benmoxin is combined with Oxycodone.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Oxycodone is combined with Benperidol.Investigational
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Oxycodone.Approved
BenzocaineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Benzocaine.Approved
BenzphetamineBenzphetamine may increase the analgesic activities of Oxycodone.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Oxycodone is combined with Benzyl alcohol.Approved
BetaxololThe metabolism of Oxycodone can be decreased when combined with Betaxolol.Approved
BexaroteneThe serum concentration of Oxycodone can be decreased when it is combined with Bexarotene.Approved, Investigational
BiperidenThe risk or severity of adverse effects can be increased when Biperiden is combined with Oxycodone.Approved
BL-1020BL-1020 may increase the hypotensive activities of Oxycodone.Investigational
BoceprevirThe risk or severity of adverse effects can be increased when Boceprevir is combined with Oxycodone.Approved
BortezomibThe risk or severity of adverse effects can be increased when Bortezomib is combined with Oxycodone.Approved, Investigational
BosentanThe serum concentration of Oxycodone can be decreased when it is combined with Bosentan.Approved, Investigational
BrexpiprazoleThe risk or severity of adverse effects can be increased when Oxycodone is combined with Brexpiprazole.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Brimonidine.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Oxycodone.Approved
BromazepamThe risk or severity of adverse effects can be increased when Oxycodone is combined with Bromazepam.Approved, Illicit
BrompheniramineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Oxycodone is combined with Brotizolam.Approved, Withdrawn
BumetanideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Oxycodone.Approved, Investigational
BuprenorphineOxycodone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Oxycodone can be decreased when combined with Bupropion.Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Oxycodone.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Oxycodone.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Oxycodone is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Oxycodone is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Oxycodone is combined with Butethal.Approved, Illicit
ButorphanolButorphanol may decrease the analgesic activities of Oxycodone.Approved, Illicit, Vet Approved
Canrenoic acidThe risk or severity of adverse effects can be increased when Oxycodone is combined with Canrenoic acid.Approved, Withdrawn
CanrenoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Canrenone.Investigational
CarbamazepineThe metabolism of Oxycodone can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Oxycodone is combined with Carfentanil.Illicit, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Oxycodone is combined with Carisoprodol.Approved
CaroxazoneThe risk or severity of adverse effects can be increased when Caroxazone is combined with Oxycodone.Withdrawn
CelecoxibThe metabolism of Oxycodone can be decreased when combined with Celecoxib.Approved, Investigational
CeritinibThe risk or severity of adverse effects can be increased when Ceritinib is combined with Oxycodone.Approved
CetirizineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Oxycodone is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Oxycodone.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Chlormezanone.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Chloroprocaine.Approved
ChloroquineThe metabolism of Oxycodone can be decreased when combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Chlorothiazide.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Chlorphenamine.Approved
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Oxycodone.Withdrawn
ChlorphentermineChlorphentermine may increase the analgesic activities of Oxycodone.Illicit, Withdrawn
ChlorpromazineThe metabolism of Oxycodone can be decreased when combined with Chlorpromazine.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Chlorprothixene.Approved, Withdrawn
ChlorthalidoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Chlorthalidone.Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Chlorzoxazone.Approved
CholecalciferolThe metabolism of Oxycodone can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CicletanineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Cicletanine.Investigational
CimetidineThe metabolism of Oxycodone can be decreased when combined with Cimetidine.Approved
CinacalcetThe metabolism of Oxycodone can be decreased when combined with Cinacalcet.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Cinchocaine.Approved, Vet Approved
CitalopramThe metabolism of Oxycodone can be decreased when combined with Citalopram.Approved
ClarithromycinThe risk or severity of adverse effects can be increased when Clarithromycin is combined with Oxycodone.Approved
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Oxycodone.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Oxycodone is combined with Clidinium.Approved
ClobazamThe metabolism of Oxycodone can be decreased when combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Oxycodone is combined with clomethiazole.Investigational
ClomipramineThe metabolism of Oxycodone can be decreased when combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Oxycodone is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Clonidine.Approved
ClorazepateThe risk or severity of adverse effects can be increased when Oxycodone is combined with Clorazepate.Approved, Illicit
ClotrimazoleThe risk or severity of adverse effects can be increased when Clotrimazole is combined with Oxycodone.Approved, Vet Approved
ClozapineThe metabolism of Oxycodone can be decreased when combined with Clozapine.Approved
CobicistatThe risk or severity of adverse effects can be increased when Cobicistat is combined with Oxycodone.Approved
CocaineThe metabolism of Oxycodone can be decreased when combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Oxycodone.Approved, Illicit
ConivaptanThe serum concentration of Oxycodone can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibThe risk or severity of adverse effects can be increased when Crizotinib is combined with Oxycodone.Approved
CyclizineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Cyclobenzaprine.Approved
CyclopentolateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Oxycodone.Approved
CyclosporineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Oxycodone.Approved, Investigational, Vet Approved
CyclothiazideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Cyclothiazide.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Cyproheptadine.Approved
DabrafenibThe serum concentration of Oxycodone can be decreased when it is combined with Dabrafenib.Approved
DantroleneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Oxycodone.Approved
DapoxetineOxycodone may increase the serotonergic activities of Dapoxetine.Investigational
DarifenacinThe metabolism of Oxycodone can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe risk or severity of adverse effects can be increased when Darunavir is combined with Oxycodone.Approved
DasatinibThe serum concentration of Oxycodone can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Oxycodone can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe risk or severity of adverse effects can be increased when Delavirdine is combined with Oxycodone.Approved
deramciclaneThe risk or severity of adverse effects can be increased when Oxycodone is combined with deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Desflurane.Approved
DesipramineThe metabolism of Oxycodone can be decreased when combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Desloratadine.Approved, Investigational
DesmopressinThe risk or severity of adverse effects can be increased when Oxycodone is combined with Desmopressin.Approved
DesvenlafaxineOxycodone may increase the serotonergic activities of Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Detomidine.Vet Approved
DexamethasoneThe serum concentration of Oxycodone can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Dexbrompheniramine.Approved
DexetimideThe risk or severity of adverse effects can be increased when Dexetimide is combined with Oxycodone.Withdrawn
DexmedetomidineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Dexmedetomidine.Approved, Vet Approved
DextroamphetamineDextroamphetamine may increase the analgesic activities of Oxycodone.Approved, Illicit
DextromoramideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Dextropropoxyphene.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Dezocine.Approved
DiazepamThe risk or severity of adverse effects can be increased when Oxycodone is combined with Diazepam.Approved, Illicit, Vet Approved
DicyclomineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Oxycodone.Approved
DiethylpropionDiethylpropion may increase the analgesic activities of Oxycodone.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Oxycodone is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Dihydrocodeine.Approved, Illicit
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Oxycodone.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Dihydromorphine.Experimental, Illicit
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Oxycodone.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Oxycodone is combined with Dimenhydrinate.Approved
DiphenhydramineThe metabolism of Oxycodone can be decreased when combined with Diphenhydramine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Oxycodone is combined with Diphenoxylate.Approved, Illicit
DoramectinThe risk or severity of adverse effects can be increased when Oxycodone is combined with Doramectin.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Oxycodone is combined with Doxepin.Approved
DoxycyclineThe risk or severity of adverse effects can be increased when Doxycycline is combined with Oxycodone.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Oxycodone.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Oxycodone is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Oxycodone.Approved, Illicit
DronedaroneThe risk or severity of adverse effects can be increased when Dronedarone is combined with Oxycodone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Oxycodone.Approved, Vet Approved
DrospirenoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Drospirenone.Approved
DrotebanolThe risk or severity of adverse effects can be increased when Oxycodone is combined with Drotebanol.Experimental, Illicit
DuloxetineThe metabolism of Oxycodone can be decreased when combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Dyclonine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Ecgonine.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Oxycodone is combined with ECGONINE METHYL ESTER.Experimental
EcopipamThe risk or severity of adverse effects can be increased when Oxycodone is combined with Ecopipam.Investigational
EfavirenzThe serum concentration of Oxycodone can be decreased when it is combined with Efavirenz.Approved, Investigational
EfonidipineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Efonidipine.Approved
EliglustatThe metabolism of Oxycodone can be decreased when combined with Eliglustat.Approved
EluxadolineOxycodone may increase the constipating activities of Eluxadoline.Approved
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Oxycodone.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Oxycodone is combined with Entacapone.Approved, Investigational
EnzalutamideThe serum concentration of Oxycodone can be decreased when it is combined with Enzalutamide.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Eplerenone.Approved
ErythromycinThe risk or severity of adverse effects can be increased when Erythromycin is combined with Oxycodone.Approved, Vet Approved
EscitalopramOxycodone may increase the serotonergic activities of Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Oxycodone can be decreased when it is combined with Eslicarbazepine acetate.Approved
EstazolamThe risk or severity of adverse effects can be increased when Oxycodone is combined with Estazolam.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Oxycodone.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Oxycodone is combined with Etacrynic acid.Approved
EthanolOxycodone may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Oxycodone.Approved, Illicit, Withdrawn
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Oxycodone.Approved
EthosuximideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Oxycodone is combined with Ethotoin.Approved
EthoxzolamideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Ethoxzolamide.Withdrawn
Ethyl carbamateThe risk or severity of adverse effects can be increased when Oxycodone is combined with Ethyl carbamate.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Oxycodone is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Etifoxine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Oxycodone is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Oxycodone.Approved
EtoperidoneOxycodone may increase the serotonergic activities of Etoperidone.Approved
EtorphineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Etorphine.Illicit, Vet Approved
EtravirineThe serum concentration of Oxycodone can be decreased when it is combined with Etravirine.Approved
EzogabineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Oxycodone is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Fencamfamine.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Oxycodone is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Oxycodone.Approved
FexofenadineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Fexofenadine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Oxycodone is combined with Flibanserin.Approved
FluconazoleThe risk or severity of adverse effects can be increased when Fluconazole is combined with Oxycodone.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Oxycodone is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Oxycodone is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe metabolism of Oxycodone can be decreased when combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Oxycodone is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Fluphenazine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Oxycodone is combined with Flurazepam.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Fluspirilene.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Oxycodone is combined with Fluticasone Propionate.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Oxycodone.Approved, Investigational
FosamprenavirThe risk or severity of adverse effects can be increased when Fosamprenavir is combined with Oxycodone.Approved
FosaprepitantThe serum concentration of Oxycodone can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Oxycodone can be increased when combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Oxycodone is combined with Fospropofol.Approved, Illicit
FurazolidoneThe risk or severity of adverse effects can be increased when Furazolidone is combined with Oxycodone.Approved, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Oxycodone can be increased when it is combined with Fusidic Acid.Approved
GabapentinThe risk or severity of adverse effects can be increased when Oxycodone is combined with Gabapentin.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Oxycodone is combined with gabapentin enacarbil.Approved
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Oxycodone.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Oxycodone is combined with Gamma Hydroxybutyric Acid.Approved, Illicit
GepironeThe risk or severity of adverse effects can be increased when Oxycodone is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Glutethimide.Approved, Illicit
GlycopyrroniumThe risk or severity of adverse effects can be increased when Glycopyrronium is combined with Oxycodone.Approved, Investigational, Vet Approved
GuanfacineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Oxycodone is combined with Halazepam.Approved, Illicit, Withdrawn
HaloperidolThe metabolism of Oxycodone can be decreased when combined with Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Halothane.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Oxycodone is combined with Heroin.Approved, Illicit
HexamethoniumThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Oxycodone.Experimental
HexobarbitalThe risk or severity of adverse effects can be increased when Oxycodone is combined with Hexobarbital.Approved
HomatropineThe risk or severity of adverse effects can be increased when Homatropine is combined with Oxycodone.Approved
HydracarbazineThe risk or severity of adverse effects can be increased when Hydracarbazine is combined with Oxycodone.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneOxycodone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydroflumethiazideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Hydroflumethiazide.Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Oxycodone.Approved, Illicit
Hydroxyamphetamine hydrobromideHydroxyamphetamine hydrobromide may increase the analgesic activities of Oxycodone.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Oxycodone.Approved
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Oxycodone.Approved
IdelalisibThe serum concentration of Oxycodone can be increased when it is combined with Idelalisib.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Iloperidone.Approved
ImatinibThe risk or severity of adverse effects can be increased when Imatinib is combined with Oxycodone.Approved
ImipramineThe metabolism of Oxycodone can be decreased when combined with Imipramine.Approved
IndalpineOxycodone may increase the serotonergic activities of Indalpine.Investigational, Withdrawn
IndapamideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Indapamide.Approved
IndinavirThe risk or severity of adverse effects can be increased when Indinavir is combined with Oxycodone.Approved
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Oxycodone.Approved
IproclozideThe risk or severity of adverse effects can be increased when Iproclozide is combined with Oxycodone.Withdrawn
IproniazidThe risk or severity of adverse effects can be increased when Iproniazid is combined with Oxycodone.Withdrawn
IsavuconazoniumThe risk or severity of adverse effects can be increased when Isavuconazonium is combined with Oxycodone.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Oxycodone.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Isoflurane.Approved, Vet Approved
IsoniazidThe metabolism of Oxycodone can be decreased when combined with Isoniazid.Approved
IsosorbideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Isosorbide.Approved
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Oxycodone.Approved
ItraconazoleThe risk or severity of adverse effects can be increased when Itraconazole is combined with Oxycodone.Approved, Investigational
IvacaftorThe serum concentration of Oxycodone can be increased when it is combined with Ivacaftor.Approved
KetamineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Ketamine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Oxycodone is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Ketobemidone.Approved
KetoconazoleThe risk or severity of adverse effects can be increased when Ketoconazole is combined with Oxycodone.Approved, Investigational
KW-3902The risk or severity of adverse effects can be increased when Oxycodone is combined with KW-3902.Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Lamotrigine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Oxycodone is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Levobupivacaine.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Oxycodone is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Oxycodone is combined with Levomethadyl Acetate.Approved
LevomilnacipranOxycodone may increase the serotonergic activities of Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Oxycodone is combined with Levorphanol.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Oxycodone.Approved, Vet Approved
LisdexamfetamineLisdexamfetamine may increase the analgesic activities of Oxycodone.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Oxycodone is combined with Lithium.Approved
LofentanilThe risk or severity of adverse effects can be increased when Oxycodone is combined with Lofentanil.Illicit
LopinavirThe risk or severity of adverse effects can be increased when Lopinavir is combined with Oxycodone.Approved
LoratadineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Oxycodone.Approved
LorcaserinThe metabolism of Oxycodone can be decreased when combined with Lorcaserin.Approved
LovastatinThe risk or severity of adverse effects can be increased when Lovastatin is combined with Oxycodone.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Oxycodone.Approved
Lu AA21004The risk or severity of adverse effects can be increased when Oxycodone is combined with Lu AA21004.Investigational
LuliconazoleThe risk or severity of adverse effects can be increased when Luliconazole is combined with Oxycodone.Approved
LumacaftorThe metabolism of Oxycodone can be increased when combined with Lumacaftor.Approved
LumefantrineThe metabolism of Oxycodone can be decreased when combined with Lumefantrine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Lurasidone.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Oxycodone.Approved, Vet Approved
MannitolThe risk or severity of adverse effects can be increased when Oxycodone is combined with Mannitol.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Maprotiline.Approved
MebanazineThe risk or severity of adverse effects can be increased when Mebanazine is combined with Oxycodone.Withdrawn
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Oxycodone.Approved
MeclizineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Meclizine.Approved
MedetomidineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Medetomidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Oxycodone is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Melperone.Approved
MephedroneMephedrone may increase the analgesic activities of Oxycodone.Investigational
MephentermineMephentermine may increase the analgesic activities of Oxycodone.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Oxycodone.Approved, Illicit
MersalylThe risk or severity of adverse effects can be increased when Oxycodone is combined with Mersalyl.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Mesoridazine.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Metaxalone.Approved
MethadoneThe metabolism of Oxycodone can be decreased when combined with Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Oxycodone is combined with Methadyl Acetate.Approved, Illicit
MethamphetamineMethamphetamine may increase the analgesic activities of Oxycodone.Approved, Illicit
MethanthelineThe risk or severity of adverse effects can be increased when Methantheline is combined with Oxycodone.Approved
MethapyrileneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Methaqualone.Illicit, Withdrawn
MethazolamideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Methazolamide.Approved
MethocarbamolThe risk or severity of adverse effects can be increased when Oxycodone is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Oxycodone.Approved
MethotrimeprazineOxycodone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Methoxyflurane.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Methsuximide.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Methyclothiazide.Approved
Methylene blueThe risk or severity of adverse effects can be increased when Methylene blue is combined with Oxycodone.Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Oxycodone is combined with Methylphenobarbital.Approved
MetixeneThe risk or severity of adverse effects can be increased when Metixene is combined with Oxycodone.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Metolazone.Approved
MetoprololThe metabolism of Oxycodone can be decreased when combined with Metoprolol.Approved, Investigational
MetyrosineOxycodone may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Oxycodone is combined with Midazolam.Approved, Illicit
MifepristoneThe serum concentration of Oxycodone can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranOxycodone may increase the serotonergic activities of Milnacipran.Approved
MinaprineThe risk or severity of adverse effects can be increased when Minaprine is combined with Oxycodone.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Oxycodone.Approved, Investigational
MirabegronThe metabolism of Oxycodone can be decreased when combined with Mirabegron.Approved
MirtazapineOxycodone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitotaneThe serum concentration of Oxycodone can be decreased when it is combined with Mitotane.Approved
MMDAMMDA may increase the analgesic activities of Oxycodone.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Oxycodone.Approved
ModafinilThe serum concentration of Oxycodone can be decreased when it is combined with Modafinil.Approved, Investigational
MolindoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Molindone.Approved
MoricizineMoricizine may increase the hypotensive activities of Oxycodone.Approved, Withdrawn
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Oxycodone.Approved, Investigational
N-butylscopolammonium bromideThe risk or severity of adverse effects can be increased when N-butylscopolammonium bromide is combined with Oxycodone.Vet Approved
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Oxycodone.Approved, Investigational
NafcillinThe serum concentration of Oxycodone can be decreased when it is combined with Nafcillin.Approved
NalbuphineNalbuphine may decrease the analgesic activities of Oxycodone.Approved
NaltrexoneThe therapeutic efficacy of Oxycodone can be decreased when used in combination with Naltrexone.Approved, Investigational, Vet Approved
NefazodoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Oxycodone.Approved, Withdrawn
NelfinavirThe risk or severity of adverse effects can be increased when Nelfinavir is combined with Oxycodone.Approved
NetupitantThe risk or severity of adverse effects can be increased when Netupitant is combined with Oxycodone.Approved
NevirapineThe risk or severity of adverse effects can be increased when Nevirapine is combined with Oxycodone.Approved
NialamideThe risk or severity of adverse effects can be increased when Nialamide is combined with Oxycodone.Withdrawn
NicardipineThe metabolism of Oxycodone can be decreased when combined with Nicardipine.Approved
NilotinibThe risk or severity of adverse effects can be increased when Nilotinib is combined with Oxycodone.Approved, Investigational
NitrazepamThe risk or severity of adverse effects can be increased when Oxycodone is combined with Nitrazepam.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Nitrous oxide.Approved, Vet Approved
NormethadoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Nortriptyline.Approved
NVA237The risk or severity of adverse effects can be increased when NVA237 is combined with Oxycodone.Investigational
OctamoxinThe risk or severity of adverse effects can be increased when Octamoxin is combined with Oxycodone.Withdrawn
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Oxycodone.Approved, Investigational
OlaparibThe risk or severity of adverse effects can be increased when Olaparib is combined with Oxycodone.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Olopatadine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Oxycodone is combined with Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Oxycodone is combined with Opium.Approved, Illicit
OrphenadrineOxycodone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Oxycodone is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Oxycodone can be increased when it is combined with Osimertinib.Approved
OxazepamThe risk or severity of adverse effects can be increased when Oxycodone is combined with Oxazepam.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Oxetacaine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Oxycodone is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Oxybuprocaine.Approved
OxybutyninThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Oxycodone.Approved, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Oxymorphone.Approved, Investigational, Vet Approved
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Oxycodone.Approved
PalbociclibThe serum concentration of Oxycodone can be increased when it is combined with Palbociclib.Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Paliperidone.Approved
PancuroniumThe risk or severity of adverse effects can be increased when Pancuronium is combined with Oxycodone.Approved
PanobinostatThe serum concentration of Oxycodone can be increased when it is combined with Panobinostat.Approved, Investigational
ParaldehydeOxycodone may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
PargylineThe risk or severity of adverse effects can be increased when Pargyline is combined with Oxycodone.Approved
ParoxetineThe metabolism of Oxycodone can be decreased when combined with Paroxetine.Approved, Investigational
Peginterferon alfa-2bThe serum concentration of Oxycodone can be decreased when it is combined with Peginterferon alfa-2b.Approved
PegvisomantThe therapeutic efficacy of Pegvisomant can be decreased when used in combination with Oxycodone.Approved
PentazocinePentazocine may decrease the analgesic activities of Oxycodone.Approved, Vet Approved
PentobarbitalThe metabolism of Oxycodone can be increased when combined with Pentobarbital.Approved, Vet Approved
PentoliniumThe risk or severity of adverse effects can be increased when Pentolinium is combined with Oxycodone.Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Oxycodone.Approved
PerazineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Perazine.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Oxycodone is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Perphenazine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Oxycodone.Approved
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Oxycodone.Approved
PheniprazineThe risk or severity of adverse effects can be increased when Pheniprazine is combined with Oxycodone.Withdrawn
PhenobarbitalThe metabolism of Oxycodone can be increased when combined with Phenobarbital.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Oxycodone is combined with Phenoxyethanol.Approved
PhenoxypropazineThe risk or severity of adverse effects can be increased when Phenoxypropazine is combined with Oxycodone.Withdrawn
PhenterminePhentermine may increase the analgesic activities of Oxycodone.Approved, Illicit
PhenytoinThe metabolism of Oxycodone can be increased when combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Pimozide.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Pipamperone.Approved
PipecuroniumThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Oxycodone.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Pipotiazine.Approved
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Oxycodone.Approved
PiretanideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Piretanide.Experimental
PiritramideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Piritramide.Investigational
PirlindoleThe risk or severity of adverse effects can be increased when Pirlindole is combined with Oxycodone.Approved
PivhydrazineThe risk or severity of adverse effects can be increased when Pivhydrazine is combined with Oxycodone.Withdrawn
PizotifenThe risk or severity of adverse effects can be increased when Oxycodone is combined with Pizotifen.Approved
PolythiazideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Polythiazide.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Pomalidomide.Approved
PosaconazoleThe risk or severity of adverse effects can be increased when Posaconazole is combined with Oxycodone.Approved, Investigational, Vet Approved
PotassiumThe risk or severity of adverse effects can be increased when Oxycodone is combined with Potassium.Approved
Potassium CitrateThe risk or severity of adverse effects can be increased when Oxycodone is combined with Potassium Citrate.Approved, Vet Approved
PramipexoleOxycodone may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Oxycodone is combined with Prazepam.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Oxycodone.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Pregnanolone.Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Prilocaine.Approved
PrimidoneThe metabolism of Oxycodone can be increased when combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Procaine.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Oxycodone.Approved, Vet Approved
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Oxycodone.Approved
PromazineThe metabolism of Oxycodone can be decreased when combined with Promazine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Promethazine.Approved
PropanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with Oxycodone.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Proparacaine.Approved, Vet Approved
PropiopromazinePropiopromazine may increase the hypotensive activities of Oxycodone.Vet Approved
PropiverineThe risk or severity of adverse effects can be increased when Propiverine is combined with Oxycodone.Investigational
PropofolThe risk or severity of adverse effects can be increased when Oxycodone is combined with Propofol.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Propoxycaine.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Protriptyline.Approved
PSD502The risk or severity of adverse effects can be increased when Oxycodone is combined with PSD502.Investigational
PseudoephedrinePseudoephedrine may increase the analgesic activities of Oxycodone.Approved
QuazepamThe risk or severity of adverse effects can be increased when Oxycodone is combined with Quazepam.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Quetiapine.Approved
QuinethazoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Quinethazone.Approved
QuinidineThe metabolism of Oxycodone can be decreased when combined with Quinidine.Approved
QuinineThe metabolism of Oxycodone can be decreased when combined with Quinine.Approved
RacloprideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Oxycodone is combined with Ramelteon.Approved, Investigational
RamosetronOxycodone may increase the constipating activities of Ramosetron.Approved
RanolazineThe risk or severity of adverse effects can be increased when Ranolazine is combined with Oxycodone.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Oxycodone.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Oxycodone is combined with Remifentanil.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Oxycodone.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Oxycodone.Approved
RifabutinThe metabolism of Oxycodone can be increased when combined with Rifabutin.Approved
RifampicinThe serum concentration of Oxycodone can be decreased when it is combined with Rifampicin.Approved
RifapentineThe metabolism of Oxycodone can be increased when combined with Rifapentine.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Risperidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Oxycodone is combined with Ritanserin.Investigational
RitobegronRitobegron may increase the analgesic activities of Oxycodone.Investigational
RitonavirThe risk or severity of adverse effects can be increased when Ritonavir is combined with Oxycodone.Approved, Investigational
RolapitantThe metabolism of Oxycodone can be decreased when combined with Rolapitant.Approved
RolofyllineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Rolofylline.Investigational
RomifidineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Romifidine.Vet Approved
RopiniroleOxycodone may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Oxycodone.Approved
RotigotineOxycodone may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Oxycodone.Approved
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Oxycodone is combined with S-Ethylisothiourea.Experimental
SafrazineThe risk or severity of adverse effects can be increased when Safrazine is combined with Oxycodone.Withdrawn
Sage 547The risk or severity of adverse effects can be increased when Oxycodone is combined with Sage 547.Investigational
SaquinavirThe risk or severity of adverse effects can be increased when Saquinavir is combined with Oxycodone.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Scopolamine.Approved
Scopolamine butylbromideThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Oxycodone.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Oxycodone.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Oxycodone.Approved, Investigational, Vet Approved
SertindoleThe risk or severity of adverse effects can be increased when Oxycodone is combined with Sertindole.Approved, Withdrawn
SertralineThe metabolism of Oxycodone can be decreased when combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Sevoflurane.Approved, Vet Approved
SildenafilThe risk or severity of adverse effects can be increased when Sildenafil is combined with Oxycodone.Approved, Investigational
SiltuximabThe serum concentration of Oxycodone can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Oxycodone can be increased when it is combined with Simeprevir.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Oxycodone.Approved
SolifenacinThe risk or severity of adverse effects can be increased when Solifenacin is combined with Oxycodone.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Spironolactone.Approved
St. John's WortThe serum concentration of Oxycodone can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Oxycodone can be increased when it is combined with Stiripentol.Approved
SuccinylcholineSuccinylcholine may increase the bradycardic activities of Oxycodone.Approved
SufentanilThe risk or severity of adverse effects can be increased when Oxycodone is combined with Sufentanil.Approved, Investigational
SulfisoxazoleThe risk or severity of adverse effects can be increased when Sulfisoxazole is combined with Oxycodone.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Oxycodone.Approved
SuvorexantOxycodone may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TandospironeThe risk or severity of adverse effects can be increased when Oxycodone is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Oxycodone.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Oxycodone is combined with Tasimelteon.Approved
TelaprevirThe risk or severity of adverse effects can be increased when Telaprevir is combined with Oxycodone.Approved
TelithromycinThe risk or severity of adverse effects can be increased when Telithromycin is combined with Oxycodone.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Oxycodone.Approved
TerbinafineThe metabolism of Oxycodone can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Tetracaine.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Oxycodone is combined with Tetrodotoxin.Investigational
ThalidomideOxycodone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheobromineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Theobromine.Approved
ThiamylalThe risk or severity of adverse effects can be increased when Oxycodone is combined with Thiamylal.Approved, Vet Approved
ThiethylperazineThiethylperazine may increase the hypotensive activities of Oxycodone.Withdrawn
ThiopentalThe risk or severity of adverse effects can be increased when Oxycodone is combined with Thiopental.Approved, Vet Approved
ThioridazineThe metabolism of Oxycodone can be decreased when combined with Thioridazine.Approved
ThiothixeneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Thiothixene.Approved
TiagabineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Tiapride.Investigational
TiclopidineThe risk or severity of adverse effects can be increased when Ticlopidine is combined with Oxycodone.Approved
TicrynafenThe risk or severity of adverse effects can be increased when Oxycodone is combined with Ticrynafen.Withdrawn
TiletamineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Tiletamine.Vet Approved
TiotropiumThe risk or severity of adverse effects can be increased when Tiotropium is combined with Oxycodone.Approved
TipranavirThe metabolism of Oxycodone can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Tizanidine.Approved
TocilizumabThe serum concentration of Oxycodone can be decreased when it is combined with Tocilizumab.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Oxycodone is combined with Tolcapone.Approved, Withdrawn
ToloxatoneThe risk or severity of adverse effects can be increased when Toloxatone is combined with Oxycodone.Approved
TolterodineThe risk or severity of adverse effects can be increased when Tolterodine is combined with Oxycodone.Approved, Investigational
TolvaptanThe risk or severity of adverse effects can be increased when Oxycodone is combined with Tolvaptan.Approved
TopiramateThe risk or severity of adverse effects can be increased when Oxycodone is combined with Topiramate.Approved
TorasemideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Torasemide.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Oxycodone.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Oxycodone.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Oxycodone.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Trazodone.Approved, Investigational
TriamtereneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Triamterene.Approved
TriazolamThe risk or severity of adverse effects can be increased when Oxycodone is combined with Triazolam.Approved
TrichlormethiazideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Trichlormethiazide.Approved, Vet Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Trifluoperazine.Approved
TriflupromazineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Triflupromazine.Approved, Vet Approved
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Oxycodone.Approved
TrimethaphanThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Oxycodone.Approved
TrimipramineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Triprolidine.Approved
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Oxycodone.Approved
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Oxycodone.Approved
TubocurarineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Oxycodone.Approved
Uc1010The risk or severity of adverse effects can be increased when Oxycodone is combined with Uc1010.Investigational
UlaritideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Ularitide.Investigational
UmeclidiniumThe risk or severity of adverse effects can be increased when Umeclidinium is combined with Oxycodone.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Oxycodone.Approved, Investigational
VecuroniumThe risk or severity of adverse effects can be increased when Vecuronium is combined with Oxycodone.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Oxycodone.Approved
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Oxycodone.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Oxycodone is combined with Vigabatrin.Approved
VoriconazoleThe risk or severity of adverse effects can be increased when Voriconazole is combined with Oxycodone.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Vortioxetine.Approved
XylazineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Oxycodone is combined with Zaleplon.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Ziconotide.Approved
ZimelidineOxycodone may increase the serotonergic activities of Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Oxycodone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Oxycodone is combined with Zolazepam.Vet Approved
ZolpidemOxycodone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Oxycodone is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Zopiclone.Approved
ZotepineThe risk or severity of adverse effects can be increased when Oxycodone is combined with Zotepine.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Oxycodone is combined with Zuclopenthixol.Approved, Investigational
Food Interactions
  • Take without regard to meals. Avoid alcohol.
References
Synthesis Reference

Bao-Shan Huang, Yansong Lu, Ben-Yi Ji, Aris P Christodoulou, “Preparation of oxycodone from codeine.” U.S. Patent US6008355, issued March, 1990.

US6008355
General References
  1. Ordonez Gallego A, Gonzalez Baron M, Espinosa Arranz E: Oxycodone: a pharmacological and clinical review. Clin Transl Oncol. 2007 May;9(5):298-307. [PubMed:17525040 ]
  2. Riley J, Eisenberg E, Muller-Schwefe G, Drewes AM, Arendt-Nielsen L: Oxycodone: a review of its use in the management of pain. Curr Med Res Opin. 2008 Jan;24(1):175-92. [PubMed:18039433 ]
External Links
ATC CodesN02AA55N02AA05
AHFS Codes
  • 28:08.08
PDB EntriesNot Available
FDA labelDownload (689 KB)
MSDSDownload (50.5 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9924
Blood Brain Barrier+0.9885
Caco-2 permeable+0.7774
P-glycoprotein substrateSubstrate0.8996
P-glycoprotein inhibitor IInhibitor0.539
P-glycoprotein inhibitor IINon-inhibitor0.9122
Renal organic cation transporterNon-inhibitor0.5413
CYP450 2C9 substrateNon-substrate0.822
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateSubstrate0.7796
CYP450 1A2 substrateNon-inhibitor0.9327
CYP450 2C9 inhibitorNon-inhibitor0.9431
CYP450 2D6 inhibitorNon-inhibitor0.5131
CYP450 2C19 inhibitorNon-inhibitor0.882
CYP450 3A4 inhibitorNon-inhibitor0.8714
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9691
Ames testNon AMES toxic0.7337
CarcinogenicityNon-carcinogens0.9557
BiodegradationNot ready biodegradable0.9746
Rat acute toxicity3.0638 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9402
hERG inhibition (predictor II)Non-inhibitor0.9279
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Mallinckrodt inc
  • Purdue pharma lp
  • Roxane laboratories inc
  • Actavis totowa llc
  • Avanthi inc
  • Corepharma llc
  • Kv pharmaceutical co
  • Sun pharmaceutical industries inc
  • Tyco healthcare mallinckrodt
  • Vintage pharmaceuticals inc
  • Xanodyne pharmaceuticals inc
  • Endo Pharmaceuticals
Packagers
Dosage forms
FormRouteStrength
Tablet, extended releaseOral5 mg
Tablet, extended releaseOral10.0 mg
Tablet, extended releaseOral20.0 mg
Tablet, extended releaseOral40 mg
Tablet, extended releaseOral5.0 mg
Tablet, extended releaseOral80.0 mg
TabletOral7.5 mg/1
Tablet, multilayer, extended releaseOral20 mg
Capsule, gelatin coatedOral
CapsuleOral5 mg/1
SolutionOral100 mg/5mL
SolutionOral20 mg/mL
SolutionOral5 mg/5mL
Solution, concentrateOral20 mg/mL
TabletOral10 mg/1
TabletOral15 mg/1
TabletOral20 mg/1
TabletOral30 mg/1
TabletOral5 mg/1
Tablet, film coated, extended releaseOral10 mg/1
Tablet, film coated, extended releaseOral20 mg/1
Tablet, film coated, extended releaseOral40 mg/1
Tablet, film coated, extended releaseOral80 mg/1
CapsuleOral
SolutionOral
Tablet, film coatedOral
Tablet, extended releaseOral10 mg/1
Tablet, extended releaseOral20 mg/1
Tablet, extended releaseOral40 mg/1
Tablet, extended releaseOral80 mg/1
TabletOral80 mg/1
Tablet, film coated, extended releaseOral15 mg/1
Tablet, film coated, extended releaseOral30 mg/1
Tablet, film coated, extended releaseOral60 mg/1
Tablet, extended releaseOral15 mg
Tablet, extended releaseOral30 mg
Tablet, extended releaseOral60 mg
Tablet, extended releaseOral10 mg
Tablet, extended releaseOral20 mg
Tablet, extended releaseOral80 mg
TabletOral
TabletOral20 mg
SuppositoryRectal10 mg
TabletOral10 mg
SuppositoryRectal20 mg
TabletOral5 mg
Tablet, extended releaseOral
Capsule, extended releaseOral
Tablet, coatedOral
Capsule, extended releaseOral13.5 mg/1
Capsule, extended releaseOral18 mg/1
Capsule, extended releaseOral27 mg/1
Capsule, extended releaseOral36 mg/1
Capsule, extended releaseOral9 mg/1
Prices
Unit descriptionCostUnit
Oxycodone hcl powder53.64USD g
Roxicodone 5 mg/5ml Solution 500ml Bottle53.0USD bottle
Roxicodone 20 mg/ml Concentrate 30ml Bottle46.99USD bottle
OxyCODONE HCl 20 mg/ml Concentrate 30ml Bottle33.99USD bottle
Oxycontin 60 mg tablet17.08USD tablet
OxyCONTIN 80 mg 12 Hour tablet14.36USD tablet
Oxycontin 20 mg tablet11.87USD tablet
Oxycontin 80 mg tablet11.53USD tablet
OxyCONTIN 60 mg 12 Hour tablet10.57USD tablet
Oxycontin 40 mg tablet9.45USD tablet
OxyCODONE HCl 80 mg 12 Hour tablet8.33USD tablet
OxyCONTIN 40 mg 12 Hour tablet7.68USD tablet
Oxycontin 10 mg tablet6.89USD tablet
Oxycontin 30 mg tablet6.59USD tablet
OxyCONTIN 30 mg 12 Hour tablet5.8USD tablet
Roxicodone 30 mg tablet5.19USD tablet
Oxycontin 80 mg Sustained-Release Tablet4.69USD tablet
OxyCODONE HCl 40 mg 12 Hour tablet4.38USD tablet
OxyCONTIN 20 mg 12 Hour tablet4.27USD tablet
Oxycontin 60 mg Sustained-Release Tablet3.55USD tablet
Oxycontin 15 mg tablet3.22USD tablet
Supeudol 20 mg Suppository2.95USD suppository
Roxicodone 15 mg tablet2.83USD tablet
Oxycodone hcl 10 mg tablet2.82USD tablet
Endocet 10-650 mg tablet2.7USD tablet
Endocet 7.5-325 mg tablet2.54USD tablet
Oxycontin 40 mg Sustained-Release Tablet2.54USD tablet
OxyCONTIN 10 mg 12 Hour tablet2.53USD tablet
Supeudol 10 mg Suppository2.33USD suppository
Roxicodone intensol 20 mg/ml2.3USD ml
Endocet 7.5-500 mg tablet2.22USD tablet
Oxycodone-apap 2.5-325 mg tablet2.05USD tablet
Percodan 4.5-0.38-325 mg tablet1.98USD tablet
Oxycontin 30 mg Sustained-Release Tablet1.96USD tablet
Endocet 10-325 mg tablet1.87USD tablet
Endocet 5-325 tablet1.82USD tablet
Percodan tablet1.62USD tablet
Oxycontin 20 mg Sustained-Release Tablet1.46USD tablet
Dazidox 20 mg tablet1.44USD tablet
Oxycodone hcl 30 mg tablet1.41USD tablet
Oxycontin 15 mg Sustained-Release Tablet1.19USD tablet
Endodan 4.83-325 mg tablet1.18USD tablet
Oxycodone hcl 20 mg tablet1.1USD tablet
Oxycontin 10 mg Sustained-Release Tablet0.98USD tablet
Oxycodone hcl 15 mg tablet0.9USD tablet
Oxycodone hcl 5 mg tablet0.81USD tablet
Dazidox 10 mg tablet0.75USD tablet
Oxy-Ir 20 mg Tablet0.74USD tablet
OxyCODONE HCl 5 mg capsule0.71USD capsule
Oxycontin 5 mg Sustained-Release Tablet0.7USD tablet
Endocet 5-325 mg tablet0.6USD tablet
Roxicodone 5 mg tablet0.56USD tablet
Oxyir 5 mg capsule0.52USD capsule
Oxy-Ir 10 mg Tablet0.43USD tablet
Pms-Oxycodone 20 mg Tablet0.42USD tablet
Supeudol 20 mg Tablet0.42USD tablet
Oxycodone 5 mg tablet0.36USD tablet
Pms-Oxycodone 10 mg Tablet0.24USD tablet
Supeudol 10 mg Tablet0.24USD tablet
Pms-Oxycodone 5 mg Tablet0.14USD tablet
Supeudol 5 mg Tablet0.14USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2098738 No1999-08-172012-11-25Canada
US5508042 No1993-04-162013-04-16Us
US6277384 No1998-12-222018-12-22Us
US6488962 No2000-06-202020-06-20Us
US6488963 No1997-06-242017-06-24Us
US6696066 No1998-12-222018-12-22Us
US7201920 No2005-03-162025-03-16Us
US7510726 No2003-11-262023-11-26Us
US7674799 No2005-03-302025-03-30Us
US7674800 No2005-03-302025-03-30Us
US7683072 No2005-03-302025-03-30Us
US7776314 No2005-04-192025-04-19Us
US7976870 No2007-06-012027-06-01Us
US7981439 No2003-11-262023-11-26Us
US8114383 No2004-10-102024-10-10Us
US8309060 No2003-11-202023-11-20Us
US8337888 No2002-08-062022-08-06Us
US8372432 No2009-03-112029-03-11Us
US8377453 No2009-11-192029-11-19Us
US8394408 No2009-03-112029-03-11Us
US8409616 No2003-11-262023-11-26Us
US8597681 No2010-12-212030-12-21Us
US8637540 No2003-11-262023-11-26Us
US8658631 No2012-05-162032-05-16Us
US8668929 No2009-03-112029-03-11Us
US8673355 No1998-12-222018-12-22Us
US8741885 No2012-05-162032-05-16Us
US8808741 No2007-08-242027-08-24Us
US8822487 No1998-12-222018-12-22Us
US8846090 No2003-04-042023-04-04Us
US8846091 No2003-04-042023-04-04Us
US8894987 No2010-03-292030-03-29Us
US8894988 No2007-08-242027-08-24Us
US8969369 No2002-05-102022-05-10Us
US8980319 No2010-12-212030-12-21Us
US8992975 No2012-05-162032-05-16Us
US9050335 No2012-05-162032-05-16Us
US9056051 No2002-05-102022-05-10Us
US9060976 No2002-08-062022-08-06Us
US9073933 No2005-03-302025-03-30Us
US9084729 No2002-05-102022-05-10Us
US9161937 No2002-05-102022-05-10Us
US9168252 No2002-05-102022-05-10Us
US9205082 No2002-05-102022-05-10Us
US9283216 No2002-05-102022-05-10Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point219 °CPhysProp
water solubility100 mg/mlNot Available
logP0.3Not Available
Predicted Properties
PropertyValueSource
Water Solubility5.59 mg/mLALOGPS
logP1.04ALOGPS
logP1.03ChemAxon
logS-1.8ALOGPS
pKa (Strongest Acidic)13.56ChemAxon
pKa (Strongest Basic)8.21ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area59 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity84.04 m3·mol-1ChemAxon
Polarizability32.8 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-014i-6975000000-ecd49efa58246c903e23View in MoNA
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as morphinans. These are polycyclic compounds with a four-ring skeleton with three condensed six-member rings forming a partially hydrogenated phenanthrene moiety, one of which is aromatic while the two others are alicyclic.
KingdomOrganic compounds
Super ClassAlkaloids and derivatives
ClassMorphinans
Sub ClassNot Available
Direct ParentMorphinans
Alternative Parents
Substituents
  • Morphinan
  • Benzylisoquinoline
  • Phenanthrene
  • Isoquinolone
  • Tetralin
  • Benzofuran
  • Anisole
  • Aralkylamine
  • Cyclohexanone
  • Alkyl aryl ether
  • Benzenoid
  • Piperidine
  • Tertiary alcohol
  • Cyclic alcohol
  • Tertiary aliphatic amine
  • Tertiary amine
  • Ketone
  • 1,2-aminoalcohol
  • Oxacycle
  • Azacycle
  • Organoheterocyclic compound
  • Ether
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Alcohol
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Voltage-gated calcium channel activity
Specific Function:
Receptor for endogenous opioids such as beta-endorphin and endomorphin. Receptor for natural and synthetic opioids including morphine, heroin, DAMGO, fentanyl, etorphine, buprenorphin and methadone. Agonist binding to the receptor induces coupling to an inactive GDP-bound heterotrimeric G-protein complex and subsequent exchange of GDP for GTP in the G-protein alpha subunit leading to dissociati...
Gene Name:
OPRM1
Uniprot ID:
P35372
Molecular Weight:
44778.855 Da
References
  1. Ordonez Gallego A, Gonzalez Baron M, Espinosa Arranz E: Oxycodone: a pharmacological and clinical review. Clin Transl Oncol. 2007 May;9(5):298-307. [PubMed:17525040 ]
  2. Riley J, Eisenberg E, Muller-Schwefe G, Drewes AM, Arendt-Nielsen L: Oxycodone: a review of its use in the management of pain. Curr Med Res Opin. 2008 Jan;24(1):175-92. [PubMed:18039433 ]
  3. Dietis N, Guerrini R, Calo G, Salvadori S, Rowbotham DJ, Lambert DG: Simultaneous targeting of multiple opioid receptors: a strategy to improve side-effect profile. Br J Anaesth. 2009 Jul;103(1):38-49. doi: 10.1093/bja/aep129. Epub 2009 May 27. [PubMed:19474215 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Opioid receptor activity
Specific Function:
G-protein coupled opioid receptor that functions as receptor for endogenous alpha-neoendorphins and dynorphins, but has low affinity for beta-endorphins. Also functions as receptor for various synthetic opioids and for the psychoactive diterpene salvinorin A. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates th...
Gene Name:
OPRK1
Uniprot ID:
P41145
Molecular Weight:
42644.665 Da
References
  1. Ordonez Gallego A, Gonzalez Baron M, Espinosa Arranz E: Oxycodone: a pharmacological and clinical review. Clin Transl Oncol. 2007 May;9(5):298-307. [PubMed:17525040 ]
  2. Riley J, Eisenberg E, Muller-Schwefe G, Drewes AM, Arendt-Nielsen L: Oxycodone: a review of its use in the management of pain. Curr Med Res Opin. 2008 Jan;24(1):175-92. [PubMed:18039433 ]
  3. Nielsen CK, Ross FB, Lotfipour S, Saini KS, Edwards SR, Smith MT: Oxycodone and morphine have distinctly different pharmacological profiles: radioligand binding and behavioural studies in two rat models of neuropathic pain. Pain. 2007 Dec 5;132(3):289-300. Epub 2007 Apr 30. [PubMed:17467904 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Opioid receptor activity
Specific Function:
G-protein coupled receptor that functions as receptor for endogenous enkephalins and for a subset of other opioids. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling leads to the inhibition of adenylate cyclase activity. Inhibits neurot...
Gene Name:
OPRD1
Uniprot ID:
P41143
Molecular Weight:
40368.235 Da
References
  1. Ordonez Gallego A, Gonzalez Baron M, Espinosa Arranz E: Oxycodone: a pharmacological and clinical review. Clin Transl Oncol. 2007 May;9(5):298-307. [PubMed:17525040 ]
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
4. Kappa-type opioid receptor 2b
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
References
  1. Smith MT: Differences between and combinations of opioids re-visited. Curr Opin Anaesthesiol. 2008 Oct;21(5):596-601. doi: 10.1097/ACO.0b013e32830a4c4a. [PubMed:18784485 ]
Kind
Protein group
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Not Available
Specific Function:
Functions as transport protein in the blood stream. Binds various ligands in the interior of its beta-barrel domain. Also binds synthetic drugs and influences their distribution and availability in the body. Appears to function in modulating the activity of the immune system during the acute-phase reaction.
Components:
NameUniProt IDDetails
Alpha-1-acid glycoprotein 1P02763 Details
Alpha-1-acid glycoprotein 2P19652 Details
References
  1. Leow KP, Wright AW, Cramond T, Smith MT: Determination of the serum protein binding of oxycodone and morphine using ultrafiltration. Ther Drug Monit. 1993 Oct;15(5):440-7. [PubMed:8249052 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Lalovic B, Phillips B, Risler LL, Howald W, Shen DD: Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes. Drug Metab Dispos. 2004 Apr;32(4):447-54. [PubMed:15039299 ]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Lalovic B, Phillips B, Risler LL, Howald W, Shen DD: Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes. Drug Metab Dispos. 2004 Apr;32(4):447-54. [PubMed:15039299 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 04, 2016 02:53